BRAF and MEK inhibitors are currently used as a combined targeted therapy for melanoma patients to reduce possible therapeutic failure due to the activation of other pathways, including PIK3–Akt, or to the onset of other mutations occurring in the MAPK pathway [30,31]. Here, MAP2K7 is linked to melanoma.